ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials

Zhai, Jinzhao; Lu, Jiangyue; Zhang, Zhibo; Wang, Yuan; Li, Xiaoyan; Zhang, Sujie; Mu, Shuai; Zhi, Xiaoyu; Ge, Xiangwei; Lu, Di; Hu, Yi*; Wang, Jinliang*哈尔滨医科大学; 5; y
Cancer Medicine2022-5DOI: 10.1002/cam4.4589
4被引5阅读
引用收藏
分享

摘要

Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non-squamous non-small cell lung cancer (NS-NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI-chemotherapy) and bevacizumab plus chemotherapy (Bev-chemotherapy) in first-line treatment of NS-NSCLC. We identified RCTs in databases and conference abstracts presented at international conferences by Sep 1, 2021. Bayesian network meta-analysis was performed using randomized effect consistency model to estimate hazard ratio (HR) and odds ratio (OR). The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade >= 3 treatment-related adverse events (TRAEs). Fifteen RCTs (17 articles) of 6561 advanced NS-NSCLC patients receiving ICI-chemotherapy, Bev-chemotherapy, or chemotherapy at first-line were eligible for analysis. NMA results showed that first-line ICI-chemotherapy prolonged OS (HR 0.79, 0.66-0.94) in patients with advanced NS-NSCLC compared with Bev-chemotherapy, while no differences were in PFS, ORR, and grade >= 3 TRAEs (p > 0.05). Ranking plots suggested that ICI-chemotherapy had the most probability to offer the best OS (probability 0.993), PFS (probability 0.658), and ORR (probability 0.565), and Bev-chemotherapy had the most risks of grade >= 3 TRAEs (probability 0.833). Therefore, our findings showed that first-line ICI-chemotherapy was associated with better OS than Bev-chemotherapy in patients with advanced NS-NSCLC, and more clinical trials are warranted to confirm these results.

学科与关键词

关键词
bevacizumabchemotherapyimmune checkpoint inhibitornetwork meta-analysisnon-small cell lung cancer
相关
加载中…
  • Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
    Fu, Wenfan; Xu, Manman; Shi, Xingyuan; Jiang, Zeyong; Jian, Zhao; Lu, Dai*Therapeutic Advances in Chronic Disease, 2023, 14: 20406223231189224.
  • Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
    Li, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231189430.被引 1
  • Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
    Borghaeit, H.*; O'Byrnet, K. J.; Paz-Ares, L.; Ciuleanu, T. -E; Yu, X.; Pluzanski, A.; Nagrial, A.; Havel, L.; Kowalyszyn, R. D.; Valette, C. A.; Brahmer, J. R.; Reck, M.; Ramalingam, S. S.; Zhang, L.; Ntambwe, I.; Rabindran, S. K.; Nathan, F. E.; Balli, D.; Wu, Y. -L.ESMO Open, 2023, 8(6): 102065.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2022-05
卷期
第 11 卷, 第 10 期
页码
2043-2055
DOI
10.1002/cam4.4589
语言
ENGLISH
期刊等级
3区
成果收录
SCIE

作者

  • Z

    Zhai, Jinzhao (第一作者)

    5 · chinese peoples liberat army gen hosp

  • L

    Lu, Jiangyue

    harbin med univ

查看全部 12 位作者收起作者
  • Z

    Zhang, Zhibo

  • W

    Wang, Yuan

  • L

    Li, Xiaoyan

    5 · chinese peoples liberat army gen hosp

  • Z

    Zhang, Sujie

    5 · chinese peoples liberat army gen hosp

  • M

    Mu, Shuai

    5 · chinese peoples liberat army gen hosp

  • Z

    Zhi, Xiaoyu

    5 · chinese peoples liberat army gen hosp

  • G

    Ge, Xiangwei

    5 · chinese peoples liberat army gen hosp

  • L

    Lu, Di

    5 · chinese peoples liberat army gen hosp

  • H

    Hu, Yi (通讯)

    5 · chinese peoples liberat army gen hosp

  • W

    Wang, Jinliang (通讯)

    5 · chinese peoples liberat army gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417